Abstract
Availability of hematopoietic growth factors (GC-SF, GM-CSF, erythropoietin,etc.) has started a new arena of dose-intensification. The use of such growth factors has resulted in faster hematopoietic recovery of cancer patients and now offers several new treatment modifications. These include: (1)dose-intensification without hematopoietic stem cell support, (2) speedier hematopoetic recovery after hematoablative therapy and stem cell transplantation (allogeneic or autologous); (3) use of combination of growth factors, and (4) improvement in the delivery of anti-microbial drugs which are toxic towards hematopoietic cells (Gancyclovir, Bactrim,etc.). The above treatment strategies are under active clinical trials and can provide improved, cost-effective methods of treating patients with cancer.
Similar content being viewed by others
References
Lieschke G J and Burgess A W. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor.N Eng J Med,327,28–35 (1992).
Lieschke G J and Burgess A W. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor.N Eng J Med,327,99–106 (1992).
DeWitte T, Gratwohl A, Van Der Lely N, Bacigalupo A, Stern A C, Speck B, Schattenberg A, Nissen C, Gluckrnan E and Fibbe W E. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic Tcelldepleted bone marrow transplantation.Blood,79,1359–1365 (1992).
Fritsch G, Emminger W, Buchinger P, Printz D and Gadner H. CD34+ cell proportions in peripheral blood correlate with colonyforming capacity.Exp Hematol,19,1079–1083 (1991).
Siena S, Bregni M, Brando B, Belli N, Ravagnani F, Gandola L, Stern A C, Landsdorp P M, Bonadonna G and Ganni A M. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients.Blood,77,400–409 (1991).
Janssen W E, Farmelo M J, Lee C, Smilee R, Kronish L and Elfenbein G J. The CD34+ cell fraction in bone marrow and blood is not universally predictive of CFUGM.Exp Hematol 20,528–530 (1992).
Siena S, Bregni M, Gianni A M and Janssen W E. Estimation of peripheral blood CD34+ cells for autologous transplantation in cancer patients:Exp Hematol,21,203–205 (1993).
Jones R J, Sharkis S J, Celano P, Colvin O M, Rowley S C and Sensenbrenner L L. Progenitor cell assays predict hematopoietic reconstitution after syngeneic transplantation in mice.Blood,70,1186–1192 (1987).
Gulati S C.Purging in bone marrow transplantation. R.G. Landes, CRC Press, 2000 Corporate Boulevard, Boca Raton, FL 33431 (1993).
Douay L, Gorin N C, Mary J Y, Lemarie E, Lopez M, Najman A, Stachowiak J, Giarratana M C, Bailou C, Salmon C and Duhamel G. Recovery of CFUGM from cryo-preserved bone marrow andin vivo evaluation after autologous bone marrow transplantation are predictive of engraftment.Exp Hematol,14,358–365 (1986).
Atkinson K, Biggs J C, Downs K, Juttner C, Bradstock K, Lowenthal R M, Dale B, Szer J. GMCSF after allogeneic bone marrow transplantation: accelerated recovery of neutrophils, monocytes and Iymphocytes.Aust NZ J Med 21,686–692 (1991).
Nemunaitis J, Rabinowe S N, Singer J W, Bierman P J, Vose J M, Freedman A S, Onetto N, Giltis S, Oette D, Gold M, Buckner D, Hansen J A, Ritz J, Appelbaum F R, Armitage J O, Nadler L M. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for Iymphoid cancer.N Eng J Med,324,1773–1778 (1991).
Gianni A M, Bregni M, Stern A C, Siena S, Tarella C, Pileri A and Bonadonna G. granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation.Lancet, 580–585 (1989).
Gulati S C and Bennett C L. granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin Disease.Annals of lnternal Medicine,116,177–182 (1992).
Bot F J, van Eijk L, Schipper P, Backx B and Lowenberg B. Synergistic effects between GMC-SF and GC-SF or MC-SF on highly enriched human marrow progenitor cells.Leukemia,4,325–328 (1990).
Morstyn G, Campbell L, Lieschke G, Layton J E, Maher D, O’Connor M, Green M, Sheridan W, Vincent M, Alton K, Souza L, McGrath K, Fox R M. Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy.J Clin Oncol,7,1554–1562 (1989).
Bender J G, Bik To L, Williams S, Schwartzberg L S. Defining a therapeutic dose of peripheral blood stem cells.J Hematotherapy,1,329–341 (1992).
To L B, Haylock D N, Dyson P G, Thorp D, Roberts M M, Juttner C A. An unusual patter of hematopoietic reconstitution in patients with acute myeloid leukemia transplanted with autologous recovery phase peripheral blood.Bone Marrow Transplant,5,109–114 (1990).
Harrison D E, Jordan C T, Zhong R K and Astle C M. Primitive hemopoietic stem cells: direct assay of most productive populations by competitive repopulation with simple binomial, correlation and covariance calculations.Exp Hematol,21,206–219 (1993).
Lopez M, Mary J Y, Sainteny F.Invitro purging of bone marrow with mafosfamide synergizes withinvivo chemotherapy to delay the hematological recovery in a murine model of autologous bone marrow transplantation.Exp Hematol,21,311–318 (1993).
Brenner M K, Rill D, Moen R C,et al. Genemarking to trace origin of relapse after autologous bone marrow transplantation.Lancet,341,85–86 (1993).
MacKintosh F R, Adlish J, Hall S W, St.Joer S, Smith E, Tavassoli M and Zanjani E D. Suppression of normal human hematopoiesis by cytomegalovirusinvitro.Exp Hematol,21,243–250 (1993).
Schwartzberg L S, Birch R, Hazelton B, Tauer K W, Lee P Jr, Altemose R, George C, Blanco R, Wittlin F, Cohen J, Muscato J and West W H. Peripheral blood stem cell mobilization by chemotherapy with or without recombinant human granulocyte colony-stimulating factor.J Hematotherapy,1,317–327 (1992).
Moore M A S. Does stem cell exhaustion result from combining hematopoeitic growth factors with chemotherapy? If so, how do we prevent it?Blood,80,3–7 (1992).
Bitran J, White L, Okuno T, Martinec J, Samuels B and Klein L. Mobilization of early hematopoietic progenitors after high dose cyclophosphamide alone and cyclophosphamide and thiotepa.ASCO,12,1527 (1993).
Fleischlauer K, Kernan N, O’Reilly R J, Dupont B and Young Yang S. Bone marrowallograft rejection by Tlymphocytes recognizing a single amino acid difference in HLAB44.N Engl J Med,323,1381–1822 (1990).
Emerson S G, Sieff C A, Gross R G, Rozans M K, Miller R A, Rappeport J M and Nathan D G. Decreased hematopoietic accessory cell function following bone marrow transplantation.Exp Hematol,15,1013–1021 (1987).
Straus S E, Cohen J, Tosato G and Meier J. Epstein Barr virus infections: Biology, pathogenesis, and management.Annals of Internal Medicine,118,45–58 (1993).
Anderson L J and Torok T. Human Parvovirus B19.NEJM,321,536–538 (1989).
Matthews J H. Pulmonary toxicity of ABVD chemotherapy and GCSF in Hodgkin’s disease: Possible synergy.Lancet,342,988 (1993).
Iki S, Yoshinaga K, Ohbayashi Y,et al. Cytotoxic drug-induced pneumonia and possible augmentation b GCSFClinical attention.Ann Hematol 66,217–218 1993.
Brugger W, Bross K, Fisch J,et al. Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, if osfamide, and cisplatin.Blood,79,1193–1200 (1992).
Neidhart J, Mangalik A, Stidley C, Tebich S, Sarmiento L, Pfile J, Oette D and Oldhan F. Dosing regimen of granulocyte-macrophage colony-stimulating factor to support dose-intensive chemotherapy.J Clin Oncol,10,1460–1469 (1992).
Wing E J, Magee D M, Whiteside T L, Kaplan S S and Shadduck R K. Recombinant human granulocyte-macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor a and interferon in cancer patients.Blood,73,643–646 (1989).
Rabinowitz J, Petros W P, Stuart A R and Peters W P. Characterization of endogenous cytokine concentrations alter highdose chemotherapy with autologous bone marrow support.Blood,81,2452–2459 (1993).
Kawano Y, Takaue Y, Saito S I, Sato J, Shimuzu T, Suzue T, Hirao A, Okamoto Y, Abe T, Watanabe T, Kuroda Y, Kimura F, Motoyoshi K and Asano S. Granulocyte colony-stimulating factor macrophage CSF, granulocyte-macrophage CSF, interleukin-3, and interleukin-6 levels in sera from children undergoing blood stem cell autografts.Blood,81,856–860 (1993).
Locatelli F, Pedrazzoli P, Barosi G, Zecca M, Porta F, Liberato L, Gambarana D, Nespoli L and Cassola M. Recombinant human erythropoietin is effective in correcting erythropoietin-deficient anemia after allogeneic bone marrow transplantation.British J Haematol,80,545–549 (1992).
Miller C B, Platanias L C, Mills S R, Zahurak M L, Ratain M J, Ettinger D S and Jones R J. Phase 111 trial of erythropoietin in the treatment of cisplatinassociated anemia.J Natl Cancer Inst,84,98–103 (1992).
Platanias L C, Miller C B, Mick R, Hart R D, Ozer H, McEvilly J M, Jones R J and Ratain M J. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients.J Clin Oncol,9,2021–2026 (1991).
Gulati S C, Bennett C, Phillips J and Van Poznak C. GMCSF as an adjunct to autologous bone marrow transplantation.Stem Cells,11,20–25 (1993).
Crown J, Kritz A, Vahdat L, Reich L, Moore M, Hamilton N, Schneider J, Harrison M, Gilewski T, Hudis C, Gulati S C and Norton L. Rapid administration of multiple cycles of highdose myelosuppressive chemotherapy in patients with metastatic breast cancer.JCO,11,1144–1149 (1993).
Rubinstein P, Rosenfield R E, Adamson J W and Stevens C E. Stored placental blood for unrelated bone marrow reconstitution.Blood,81,1679–1690 (1993).
Brugger W, Klaus J B Glattet al. Mobilization of tumor cells and hematopoietic progenitor cell into peripheral blood of patients with solid tumors.Blood,83,636–640 (1994)
Gulati S C. Did we focus on the most important issues in the use of growth factors and stem cell transplantation?J Clin Oncol,12,650–652 (1994).
Kutsogiannis D J, Crowther M A and Lazarovitis A I, Granulocyte-macrophage colony-stimulating factor for the therapy of cytomegalovirus and gancyclovir-induced leukopenia in a renal transplant recipient.Transplantation,53,930–932 (1992).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gulati, S.C., Gopal, R., Prowda, J.B. et al. Growth factors and hematopoietic recovery. Med Oncol 11, 1–6 (1994). https://doi.org/10.1007/BF02990084
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02990084